Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate to severe plaque psoriasis.
CONCLUSIONS: Dose reduction strategies would increase ustekinumab efficiency in patients that achieve PASI 75 without psoriatic arthritis, diabetes mellitus, previous BT and concomitant treatment with conventional systemic drugs.
PMID: 29676189 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
More News: Arthritis | Databases & Libraries | Dermatology | Diabetes | Diabetes Mellitus | Endocrinology | Psoriasis | Psoriatic Arthritis | Rheumatology | Skin | Statistics | Stelara | Study